SL 052

Drug Profile

SL 052

Alternative Names: Nanoparticle formulation of SL052 (for IV administration) - Quest PharmaTech; Photodynamic cancer therapy (SL052) - Quest PharmaTech; SL 052 PDT; SL052

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quest PharmaTech
  • Developer BC Cancer Agency; National Research Council Canada; Quest PharmaTech; University of Alberta
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gastrointestinal cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer in Canada (Intra-arterial, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in Canada (IV, Injection)
  • 25 Jul 2013 SL 052 is still in phase I trials for Prostate cancer in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top